 |
Market Research Report
Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024 |
||||||
| Published by | MarketsandMarkets | Product code | 408032 | ||||
| Published | Content info | 224 Pages Delivery time: 1-2 business days |
|||||
| Price |
|
||||||
| Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024 | ||
| Published: June 25, 2019 | Content info: 224 Pages |
|
"Cancer/tumor profiling market is projected to grow at a CAGR of 10.5% during the forecast period (2019-2024)."
Cancer/tumor profiling market is projected to reach USD 12.4 billion by 2024 from USD 7.5 billion in 2019, at a CAGR of 10.5%. The increasing incidence of cancer across the globe and the rising use of biomarkers in tumor profiling are the primary growth drivers for this market. Additionally, the increase in cancer research & funding initiatives and technological advancements in profiling technologies are also propelling the growth of the cancer/tumor profiling market.
The increasing demand for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, the high capital investment required for biomarker discovery and the technical issues with sample collection and storage are the key factors restraining the market growth.
Based on technology, cancer/tumor profiling market has been segmented into immunoassays, in-situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The next-generation sequencing (NGS) segment is projected to witness the highest growth in cancer/tumor profiling market during the forecast period. The benefits of effectively exploring genetic alterations in a wide range of cancers and the identification of a number of differentially expressed genes & genetic/epigenetic variants as potential targets aid in the development of new biomarkers for early diagnosis of the disease. These factors are supporting the adoption of NGS technology in cancer/tumor profiling market.
Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing incidence of lung cancer worldwide and the growing need for early diagnosis are supporting the growth of this segment.
Based on biomarker type, cancer/tumor profiling market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. The protein biomarkers segment is estimated to grow at the highest CAGR during the forecast period majorly due to the increasing adoption of proteomic methods for biomarker research to improve the drug development process. They also showcase an enormous potential for directing personalized cancer therapy and treatment monitoring.
Based on applications, cancer/tumor profiling market is segmented into research and clinical applications. The research applications segment is further sub-segmented into biomarker discovery and personalized medicine. On the other hand, the clinical applications segment is sub-segmented into diagnostics, prognostics, screening, and monitoring & treatment.
The clinical applications segment is expected to grow at the highest CAGR during the forecast period. With the increasing incidence rate of cancers across the globe and the rising availability of molecular profiling, and functional assessment of signaling pathways of advanced solid tumors, the use of tumor profiling techniques is gaining momentum for clinical practice.
Although North America is expected to account for the largest share of global cancer/tumor profiling market in 2018, APAC is expected to witness the highest CAGR during the forecast period. This is primarily due to the high incidence of cancer, growing proteomics & genomics research, rising research funding, increasing investments by pharmaceutical & biotechnology companies, and growing awareness about personalized therapeutics.
A breakdown of the primary participants referred to for this report is provided below:
The prominent players in cancer/tumor profiling market are: Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).
The report analyzes the market for various cancer/tumor profiling technologies and their adoption pattern. It aims at estimating the market size and future growth potential of cancer/tumor profiling market and the different segments such as by technology, cancer type, biomarker type, and application. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a more significant share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers:
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
